Bristol-Myers Squibb Company (BMY)
Dividend Opportunity — Ex-Date Friday, January 2, 2026
Trade Timeline
Risk Factors
- •Overall Quality Score of 40/100 and Tier 3 classification indicate that company and dividend fundamentals are not top tier, so adverse fundamental news could override historical trading patterns.
- •ATR of 1.99% reflects meaningful short-term volatility; a single-day move can easily exceed the $0.63 dividend amount, so price risk dominates pure yield collection.
- •7-day win rate around ex-dates is only 45.7%, meaning very short-term outcomes can be negative even though longer windows and the specific 7d/1d capture setup have higher success rates.
- •Average Recovery Days of 57.4 suggests that if the price drops more than usual around ex-date and doesn’t quickly revert, capital can be tied up for nearly two months to recover.
- •Medium confidence level indicates that while historical statistics (e.g., 99.5% gap fill rate, 74.9% win rate for the 7d/1d strategy) are favorable, they are not strong enough to ignore position sizing and risk controls.
Action Checklist
- 1.Confirm ex-dividend date (2026-01-02) and ensure trading calendar around year-end/holidays does not shift timing.
- 2.Set entry plan around 7 days before ex-date (target ~2025-12-26) using limit orders near your acceptable price, considering the 1.99% ATR.
- 3.Define position size based on the Medium confidence level and the stock’s volatility, so a typical 1–2 ATR swing is acceptable for your risk tolerance.
- 4.Pre-plan an exit 1 trading day after ex-date, aligned with the Buy 7d / Sell 1d Quick Capture strategy, while monitoring intraday action for signs of abnormal downside.
- 5.Track price behavior versus the typical 99.5% 7–14 day gap-fill history; if the usual recovery pattern fails, decide in advance whether to cut losses quickly or convert to a longer recovery hold, potentially up to the 57.4-day average.
- 6.Reassess BMY’s fundamentals (earnings, pipeline, debt, payout) before converting any capture trade into a long-term position, given the 40/100 Quality and Long-Term Scores.
- 7.Log the trade (entry date, price, exit date, result) to compare your realized outcome against the historical 3.85% expected return and 74.9% win rate for future refinement.
| Strategy | Avg Return | Win Rate | Historical Events |
|---|---|---|---|
Quick CaptureBest Buy 7 days before ex-date, sell 1 day after | +3.85% | 75% | 199 ex-dates |
Same-Day Buy 1 day before ex-date, sell 1 day after | +3.58% | 72% | 199 ex-dates |
14-Day Hold Buy 1 day before ex-date, sell 14 days after | +3.94% | 69% | 199 ex-dates |
Buy 14D, Sell 7D After Buy 14 days before ex-date, sell 7 days after | +4.00% | 68% | 199 ex-dates |
Classic Capture Buy 1 day before ex-date, sell 7 days after | +3.51% | 64% | 199 ex-dates |
* Returns include dividend capture yield plus price change. Past performance does not guarantee future results.
Bristol-Myers Squibb ($BMY) offers a solid 4.63% forward yield at $54.45, but a 40/100 Quality Score and Tier 3 rating limit its appeal as a core long-term dividend holding. For dividend capture, however, the Quick Capture strategy (buy 7 days before and sell 1 day after ex-date) looks attractive, with a 3.85% expected return, 74.9% historical win rate, and very high 7–14 day gap-fill rates.
This analysis is for informational purposes only and is not financial advice. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.